Fatiguing exercise is the basis of exercise training and a cornerstone of management of type 2 2 diabetes mellitus (T2D), however, little is known about the fatigability of limb muscles and the 3 involved mechanisms in people with T2D. The purpose was to compare fatigability of knee 4 extensor muscles between people with T2D and controls without diabetes and determine the 5 neural and muscular mechanisms for a dynamic fatiguing task. Seventeen people with T2D (10 6 men, 7 women: 59.6±9.0 years) and 21 age-, BMI-and physical activity-matched controls (11 7 men, 10 women: 59.5±9.6 years) performed 120 high-velocity concentric contractions (1 8 contraction/3 s) with a load equivalent to 20% maximal voluntary isometric contraction (MVIC) 9 torque with the knee extensors. Transcranial magnetic stimulation (TMS) and electrical 10 stimulation of the quadriceps were used to assess voluntary activation and contractile properties. 11
New & Noteworthy: Transcranial magnetic stimulation and percutaneous muscle stimulation 23
were used to determine the contributions of neural and contractile mechanisms of fatigability of 24 the knee extensor muscles after a dynamic fatiguing task in men and women with type 2 diabetes 25 (T2D) and healthy, age-, BMI-and physical activity-matched controls. Although neural and 26 contractile mechanisms contributed to greater fatigability of people with T2D, fatigability was 27 primarily associated with impaired contractile mechanisms and glycemic control. 28
Key Words (5): muscle fatigue, diabetes mellitus, skeletal muscle, sex differences, knee extensors 29 Type 2 diabetes mellitus (T2D) has become a global pandemic and is estimated to 48 currently affect 8% of the world's population (34). Physical activity is a cornerstone of T2D 49 management and along with diet is the first intervention used to treat T2D (43). Incidence of 50 T2D can be reduced by 58% with lifestyle interventions (diet, weight loss and exercise), and 51 these lifestyle interventions were almost twice as effective as pharmacological treatment 52 (metformin), which reduced the incidence of diabetes by 31% (30). Fatiguing contractions of 53 limb muscles are the foundation of exercise training and the neuromuscular adaptations that 54 accompany regular exercise (31). However, there is minimal understanding of the mechanisms 55 that limit a single bout of fatiguing exercise in people with T2D. 56
Abbreviations
Fatigability of limb muscles is a reversible, short-term and activity-induced reduction in 57 muscle strength or power (17, 23), and can limit performance of daily tasks that require repeated 58 or sustained contractions (12, 42) . Mechanisms that contribute to limb fatigability in healthy 59 adults include deficits in neural drive to the muscle, impairments in neuromuscular propagation, 60 reduced force capacity of skeletal muscle fibers, and impaired blood flow to the muscle (11, 17, 61 23). Few studies have examined the mechanisms of fatigability among people with diabetes. 62 1.0 cm lateral to the vertex (over the motor area corresponding to the dominant knee extensors) 238 to ensure repeatability of coil placement during the experimental protocol. The optimal coil 239 position of the TMS was determined during brief contractions of the knee extensor muscles at 240 20% MVIC. TMS was elicited during the contractions and fine adjustments in the TMS coil 241 position (~0.5 cm) were made to determine which site evoked the largest superimposed twitch 242 (SIT) torque and MEP of the rectus femoris muscle. Optimal stimulator intensity was also 243 determined with brief contractions (2-3 s) of knee extensor muscles (50% MVIC), which is the 244 intensity that is known to elicit maximal MEPs (51). The intensity of the stimulation (% maximal 245 of stimulator intensity) was increased by 5% increments until maximal twitch torque of the 246 quadriceps and maximal MEP of the rectus femoris muscle were elicited. The brief contractions 247 at 50% MVIC were separated by 30-s rest periods to avoid fatigue when establishing the 248 intensity of TMS. 249
Electrical Stimulation 250
Single-pulse (200 µs duration, 400 V) electrical stimulation was used for femoral nerve 251 and percutaneous muscle stimulation (DS7AH; Digitimer, Ltd., Welwyn Garden City, UK) to 252 elicit maximal compound muscle action potentials (M max ) and twitch contractions at rest and 253 during MVICs of the knee extensor muscles. 254
Femoral Nerve Stimulation: The femoral nerve innervating the knee extensor muscles was 255 stimulated supramaximally (120 -600 mA) with a single pulse to elicit the maximal compound 256 muscle action potential (M max ). The cathode electrode (Ambu Neuroline electrodes, Denmark; 257 1.5 cm diameter) was placed over the femoral nerve within the femoral triangle and the anode 258 was placed over the greater trochanter of the femur. The intensity of the nerve stimulation was 259 determined by increasing the current until the twitch amplitude plateaued. The stimulationintensity was then increased further by 20% to ensure a maximal activation of the muscles within 261 the area of stimulation. 262 To assess voluntary muscle activation and twitch properties,  263 the knee extensor muscles were stimulated with a single pulse (150 -750 mA) via custom-made 264 pad electrodes (6 cm × ~15 cm) placed over the quadriceps muscles. The cathode was placed 265 near (within 10 cm) the area of the femoral triangle and the anode was placed proximal to the 266 patella without hindering knee flexion/extension of the participant. The stimulator intensity was 267 determined by increasing the current until the twitch amplitude plateaued, then the stimulation 268 intensity was increased further by 20% to ensure a maximal activation of the muscles in the area 269 of stimulation. This stimulation intensity was used for the remainder of the session. The twitch 270 amplitude elicited via percutaneous and femoral nerve stimulation were linearly correlated (r 2 = 271 0.653, P < 0.001). Percutaneous muscle stimulation was used throughout the experimental 272 protocol for assessment of voluntary activation and twitch properties, because percutaneous 273 stimulation was more tolerable than nerve stimulation. Using the supramaximal intensity, three 274 muscle stimulations were applied, each separated by ~15 s to assess electrically-evoked twitch 275 contractile properties in a non-potentiated state. 276
Percutaneous Muscle Stimulation:

Experimental Protocol 277
The experimental protocol entailed: 278 contractions. During all MVCCs, participants were instructed to "kick as hard and as fast as 301 possible" and each MVCC was initiated via strong verbal command from the authors: "KICK". 302
The authors provided the verbal cue each 3-s based on a visual cue from a custom-designed data 303 collection program, and participants were encouraged to maintain maximal effort throughout the 304 dynamic fatiguing task using several standard statements of encouragement. 305
Data Analysis 306
The torque during the MVICs was quantified as the average value over a 0. Significance was determined at P < 0.05 and all analyses were performed using IBM 364
Statistical Package for Social Sciences (SPSS, V24). 365
RESULTS
366
Baseline Measurements 367
Participant and baseline characteristics are presented in Table 1 . The T2D and control 368 groups were similar in age (group effect, P = 0.985), BMI (group effect, P = 0.172), and daily 369 physical activity (step count; group effect, P = 0.895). The control and T2D groups had similar 370 body fat (group effect, P = 0.310), estimated VO 2 peak (group effect, P = 0.231) and skeletal 371 muscle mass in the dominant leg (group effect, P = 0.724). 372
As expected, people with T2D had higher HbA 1c (group effect, P < 0.001), fasting plasma 373 glucose (group effect, P < 0.001), fasting plasma insulin (group effect, P = 0.001) and HOMA-374 IR (group effect, P < 0.001) compared with controls (Table 1) . People with T2D and controls 375 had similar plasma thyroid-stimulating hormone concentrations (1.86 ± 0.89 vs. 1.58 ± 0.89 376 mU·L -1 , respectively; group effect, P = 0.306). People with T2D and controls demonstrated no 377 signs of anemia, hemoglobin (14.2 ± 1.8 vs. 14.6 ± 1.7 g·dL -1 , respectively; group effect, P = 378 0.428) and hematocrit (42.4 ± 3.3 vs. 42.3 ± 4.0%, respectively; group effect, P = 0.974) 379 concentrations were similar between the groups. Among the people with T2D, 14 people were 380 prescribed metformin and 11 people were prescribed a statin medication. Among controls, 0 381 people were prescribed metformin and 4 people were prescribed a statin medication. Although 382 not a primary aim of the study, it is noteworthy that people with T2D prescribed to a statin 383 medication had similar reductions in MVCC power (time × statin effect, P = 0.458; statin effect, 384 P = 0.729) and MVIC torque (time × statin effect, P = 0.742; statin effect, P = 0.571) compared 385 to people with T2D not prescribed to a statin medication. See Table 1 . 386
[ Table 1 ] 387
People with T2D and controls had similar knee extensor MVIC torque (group effect, P = 388 0.421), peak angular velocities (group effect, P = 0.949), peak knee extensor power (group 389 effect, P = 0.627), electrically-evoked potentiated twitch amplitudes (group effect, P = 0.667), 390 and post-activation potentiation (group effect, P = 0.368). See Table 2 . Baseline levels of 391 voluntary activation during MVICs were similar between controls and people with T2D, 392 quantified with TMS (group effect, P = 0.232) and with electrical stimulation (group effect, P = 393 0.715; Table 2 ). 394
[ Table 2 ] 395
For both groups, men and women were similar in age (58.9 ± 9.8 vs. 60.5 ± 8.7 years, 396 respectively; sex effect, P = 0.646; group × sex, P = 0.617), BMI (28.9 ± 5.3 vs. 27.2 ± 6.2 kg·m -397 2 , sex effect, p = 0.447; group × sex, P = 0.205), daily physical activity (step count: 8,690 ± 398 3,220 vs. 7,830 ± 3,400 steps·day -1 , respectively; sex effect, P = 0.499; group × sex, P = 0.608), 399
HbA 1c (6.10 ± 1.11 vs. 6.19 ± 1.15%, respectively; sex effect, P = 0.612; group × sex, P = 400 0.568), fasting plasma glucose (106.5 ± 25.7 vs. 102.9 ± 35.2 mg·dL -1 , respectively; sex effect, P 401 = 0.614; group × sex, P = 0.786), fasting plasma insulin (46.1 ± 21.2 vs. 45.4 ± 29.0 pMol, 402 respectively; sex effect, P = 0.891; group × sex, P = 0.118), HOMA-IR (2.06 ± 1.14 vs. 2.17 ± 403 2.01 AU, respectively; sex effect, P = 0.762; group × sex, P = 0.191) and thyroid-stimulating 404 hormone (1.75 ± 1.03 vs. 1.64 ± 0.68 mU·L -1 , respectively; sex effect, P = 0.753; group × sex, P 405 = 0.520).
Men however, had less body fat than women (28.0 ± 6.6 vs. 38.3 ± 9.6%, respectively; 407 sex effect, P < 0.001, group × sex, P = 0.142) and greater skeletal muscle mass of the leg (9.81 ± 408 1.37 vs. 6.54 ± 1.24 kg, respectively; sex effect, P < 0.001; group × sex, P = 0.116). For both 409 groups men also had a larger MVIC torque (204.6 ± 63.1 vs. 116.9 ± 34.7 Nm, respectively; sex 410 effect, P < 0.001, group × sex, P = 0.905), similar MVCC peak angular velocity (342.3 ± 56.6 411 vs. 318.3 ± 41.2 deg·s -1 , respectively; sex effect, P = 0.184; group × sex, P = 0.620), greater Table 1 . 428
People with T2D and controls reported low but similar scores on the depression scale 429 (group effect, P = 0.301), with no one reporting a clinically significant level of depression (GDS 430 Table 1 . The mean scores were consistent with assessments of 'healthy control' sleepers; 432 however, some individuals reported 'poor' sleep quality (PSQI score > 5) (10). 433
Fatigability and Recovery 434
MVCC angular power and velocity: Both the control group and people with T2D had 435 reductions in MVCC power during the dynamic fatiguing task (time effect, P < 0.001), but this 436 reduction was greater in people with T2D (time × group, P < 0.001; Figure 2A ). Recovery, 437 however, was similar for both groups (time effect, P < 0.001; group effect, P = 0.291; time × 438 group, P = 0.548). 439
People with T2D demonstrated greater reductions in MVCC peak angular velocity 440 compared with controls during the dynamic fatiguing task (time effect, P < 0.001; group effect, P 441 = 0.688; time × group, P = 0.03). During recovery, both groups demonstrated increases in 442 MVCC angular velocity after the dynamic fatiguing task (time effect; P < 0.001), however, 443 people with T2D had lower MVCC angular velocity than controls throughout the recovery 444 period (R05 & R20: group effect, P = 0.012) with no interaction (time × group, P = 0.865). 445
[ Figure 2 ] 446
The reduction of MVCC power during the fatiguing task was not different between men 447 and women (last 5 contractions: 29.2 ± 20.1% vs. 38.7 ± 16.8% reduction, respectively; time × 448 sex, P = 0.524) for either group (time × group × sex, P = 0.762; sex effect, P = 0.104). During 449 recovery (R05 & R20), the increase in MVCC power (time effect, P < 0.001) was similar for 450 men and women (sex effect, P = 0.634; time × sex, P = 0.473; time × group × sex, P = 0.276). 451
Men and women demonstrated a similar reduction in MVCC velocity during the fatiguing 452 task (last 5 contractions: 23.6 ± 18.8% vs. 31.9 ± 21.2% reduction, respectively; time × sex, P = 453 0.542; time × group × sex, P = 0.621) and similar recovery after the fatiguing task (time × sex, P 454 = 0.268; time × group × sex, P = 0.669). 455
Duty Cycle: The duty cycle (work:rest ratio) was similar between people with T2D and 456 controls during the first five dynamic contractions (group effect, P = 0.146). The duty cycle 457 increased during the fatiguing task (due to slower contraction velocity), but this increase was 458 similar between people with T2D and controls (time effect, P = 0.031; time × group, P = 0.663). 459
The duty cycle was similar for men and women at the start of the fatiguing task (13.9 ± 1.8% vs. 460 14.6 ± 1.7%, respectively; sex effect, P = 0.419; group × sex, P = 0.601), and the increase in 461 duty cycle at the end of the fatiguing task was similar (27.1 ± 19.5% vs. 28.4 ± 21.3% increase, 462 respectively; time effect, P < 0.001; time × sex, P = 0.903). 
974). 472
Applied Torque: The peak applied torque during the concentric knee extension was 473 similar for people with T2D compared with controls at the start of the fatiguing task (66.9 ± 24.8 474 vs. 62.7 ± 16.5 Nm, respectively; group effect, P = 0.772). Similarly, the average applied torque 475 did not differ between the T2D and control groups (47.9 ± 19.0 vs. 43.4 ± 13.3 Nm, respectively; 476 group effect, P = 0.563). The applied torque decreased during the dynamic fatiguing task more 477 for people with T2D compared with healthy controls, for both the peak torque (19.5 ± 8.6% vs.
13.4 ± 10.3% reduction, respectively; time effect, P < 0.001; time × group, P < 0.001) and the 479 average torque (17.3 ± 11.6% vs. 12.0 ± 8.9% reduction, respectively; time effect, P < 0.001; 480 time × group, P < 0.001). 481
Because men were stronger than women, the peak applied torque (75.6 ± 21.6 vs. 62.7 ± 482 16.5 Nm, respectively; sex effect, P = 0.001) and the average applied torque (53.9 ± 16.9 Nm vs. 483
35.9 ± 8.7 Nm, respectively; sex effect, P = 0.001) during the concentric phase of the dynamic 484 knee extension was greater for men at the start of the fatiguing task. Men and women had a 485 similar reduction in both peak (14.5 ± 11.0% vs. 18.9 ± 7.8% reduction; time effect, P < 0.001; 486 time × sex, P = 0.136) and average torque (12.9 ± 11.4% vs. 16.8 ± 9.3% reduction; time effect, 487 P < 0.001; time × sex, P = 0.236) at the end of the fatiguing task. 488
MVIC Torque: The reduction in MVIC torque after the dynamic fatiguing contraction 489 (time effect, P < 0.001) was greater in the T2D group than controls (time × group, P = 0.04; 490 
Contractile Properties for the Electrically-Evoked Potentiated Twitch 500
Twitch Amplitude: The electrically-evoked potentiated twitch amplitude was reduced for 501 all participants during and immediately after the fatiguing contraction (time effect, P < 0.001);however, people with T2D had greater reductions than controls (time × group, P = 0.010). 503
Similarly, the twitch amplitude increased during recovery (time effect, P < 0.001) but people 504 with T2D recovered more slowly and the twitch was more depressed, even at 20 mins post 505 exercise, compared with controls (R05 & R20: group effect, P = 0.027). See Figure 3A . 506
[ Figure 3 ] 507
Men and women had similar reductions in potentiated twitch amplitude by the end of the 508 fatiguing task for both the T2D and control groups (40.3 ± 27.6% vs. 39.8 ± 18.0% reduction; 509 time effect, P < 0.001; sex effect, P = 0. and at 5 and 20 minutes post exercise), the half relaxation time decreased in all groups (time 518 effect, P = 0.002; group effect, P = 0.115; sex effect, P = 0.696; time × group, P = 0.458; time × 519 sex, P = 0.440; time × group × sex, P = 0.747). 520
Contraction Time: People with T2D and controls, both men and women, demonstrated no 521 change in contraction time of the electrically-evoked potentiated twitch during the fatiguing task 522 (time effect, P = 0.377; group effect, P = 0.792; sex effect, P = 0.110; time × group, P = 0.564; 523 time × sex, P = 0.212; time × group × sex, P = 0.717), or during the 20-minute recovery (task 524 end and at 5 and 20 minutes post exercise) (time effect, P = 0.532; group effect, P = 0.717; sex 525 effect, P = 0.126; time × group, P = 0.732; time × sex, P = 0.158; time × group × sex, P = 526 0.996). See Table 2 . 527
[ Table 2 ] 528
Voluntary Activation 529
Voluntary Activation (Electrical Stimulation): Voluntary activation decreased in people 530
with T2D and controls during the fatiguing contraction (End Task: 84.2 ± 9.3% vs. 86.4 ± 7.3%, 531 respectively; time effect, P < 0.001), but this decrease did not differ between groups (time × 532 group, P = 0.840; Figure 3B ). Men and women showed similar reductions in voluntary activation 533 by the end of the fatiguing contraction (87.5 ± 7.6% vs. 81.8 ± 8.1%, respectively; sex effect, P = 534 0.456; time × sex, P = 0.247; time × group × sex, P = 0.506). Voluntary activation remained 535 depressed during the recovery period after the fatiguing task for all groups (time effect, P = 536 0.408; time × group, P = 0.420; time × sex, P = 0.260; time × group × sex, P = 0.348; sex effect, 537
792). 538
Superimposed Twitch Amplitude (TMS):
The SIT increased (i.e. voluntary activation 539 decreased) in both people with T2D and controls (time effect, P = 0.015) and this effect was 540 similar for both groups (time × group, P = 0.995, Table 2 ) and for men and women across the 541 groups (sex effect, P = 0.490, time × sex, P = 0.625; time × group × sex, P = 0.717). During the 542 20-minute recovery, the superimposed twitch amplitude decreased (voluntary activation 543 increased) (time effect, P = 0.039), similarly for people with T2D and controls (time × group, P 544 = 0.600, Table 2 ) and similarly for men and women (sex effect, P = 0.944; time × sex, P = 0.146; 545 time × group × sex, P = 0.443). 546
EMG Response to Stimulation: M max , MEP, Silent Period 547
Maximal compound muscle action potential (M max ): The M max did not change during the 548 fatiguing task for participants with T2D or controls for the rectus femoris (time effect, P = 0.212; 549 time × group, P = 0.176; group effect, P = 0.392; group × sex, P = 0.805; time × sex, P = 0.357; 550 time × group × sex, P = 0.741), vastus lateralis (time effect, P = 0.697; time × group, P = 0.688;group effect, P = 0.825; group × sex, P = 0.804; time × sex, P = 0.294; time × group × sex, P = 552 0.989), or vastus medialis (time effect, P = 0.403; time × group, P = 0.449; group effect, P = 553 0.885; group × sex, P = 0.278; time × sex, P = 0.187; time × group × sex, P = 0.503). See Table  554 2. 555
The M max did not change during the 20-minute recovery period for participants with T2D 556 or controls for the rectus femoris (time effect, P = 0.588; time × group, P = 0.628; group effect, 557 P = 0.880; group × sex, P = 0.906; time × sex, P = 0.623; time × group × sex, P = 0.901), vastus 558 lateralis (time effect, P = 0.653; time × group, P = 0.763; group effect, P = 0.727; group × sex, P 559 = 0.803; time × sex, P = 0.830; time × group × sex, P = 0.973), or vastus medialis (time effect, P 560 = 0620; time × group, P = 0.736; group effect, P = 0.997; group × sex, P = 0.254; time × sex, P 561 = 0.940 time × group × sex, P = 0.157). See Table 2 . 562
Motor evoked potential (MEP):
The MEP amplitude (%M max ) evoked during the MVC 563 increased after the fatiguing task for the men and women with T2D and controls for the rectus 564 femoris (time effect, P = 0.001; time × group, P = 0.876; group effect, P = 0.422; group × sex, P 565 = 0.910; time × sex, P = 0.955; time × group × sex, P = 0.142) and vastus lateralis (time effect, P 566 = 0.037; time × group, P = 0.260; group effect, P = 0.949; group × sex, P = 0.252; time × sex, P 567 = 0.324; time × group × sex, P = 0.231), but not for the vastus medialis (time effect, P = 0.139; 568 time × group, P = 0.796; group effect, P = 0.777; group × sex, P = 0.747; time × sex, P = 0.144; 569 time × group × sex, P = 0.728). See Table 2 . 570
The MEP amplitude (%M max ) reduced during recovery for men and women with T2D and 571 controls for the rectus femoris (time effect, P < 0.001; time × group, P = 0.156; group effect, P = 572 0.176; group × sex, P = 0.986; time × sex, P = 0.588; time × group × sex, P = 0.965) and vastus 573 lateralis (time effect, P = 0.042; time × group, P = 0.521; group effect, P = 0.494; group × sex, P 574 = 0.266; time × sex, P = 0.153; time × group × sex, P = 0.305), but not for the vastus medialis 575 (time effect, P = 0.126; time × group, P = 0.958; group effect, P = 0.726; group × sex, P = 0.859; 576 time × sex, P = 0.678; time × group × sex, P = 0.952). 577
Silent Period: The EMG silent period, assessed during the MVIC, increased during the 578 fatiguing task for the rectus femoris (time effect, P < 0.001; time × group, P = 0.615; group 579 effect, P = 0.632; group × sex, P = 0.731; time × sex, P = 0.502; time × group × sex, P = 0.133), 580 vastus lateralis (time effect, P = 0.001; time × group, P = 0.187; group effect, P = 0.393; group × 581 sex, P = 0.803; time × sex, P = 0.406; time × group × sex, P = 0.245) and vastus medialis (time 582 effect, P = 0.002; time × group, P = 0.103; group effect, P = 0.189; group × sex, P = 0.516; time 583 × sex, P = 0.406; time × group × sex, P = 0.278). See Table 2 . 584
The EMG silent period decreased during recovery from the fatiguing task for men and 585 women with T2D and controls for the rectus femoris (time effect, P < 0.001; time × group, P = 586 0.800; group effect, P = 0.722; group × sex, P = 0.893; time × sex, P = 0.453; time × group × 587 sex, P = 0.585), vastus lateralis (time effect, P = 0.002; time × group, P = 0.391; group effect, P 588 = 0.447; group × sex, P = 0.660; time × sex, P = 0.275; time × group × sex, P = 0.368), and 589 vastus medialis (time effect, P = 0.042; time × group, P = 0.249; group effect, P = 0.799; group 590 × sex, P = 0.922; time × sex, P = 0.644; time × group × sex, P = 0.409). 591
Associations 592
The following variables were associated with reductions in MVIC performed after the 593 fatiguing task: the relative reduction in potentiated twitch amplitude (r 2 = 0.364, P = 0.002; 594 
DISCUSSION
602
The novel findings of this study were that people with T2D were more fatigable for a 603 high-velocity dynamic fatiguing task with the knee extensor muscles than healthy controls who 604 were matched for age, BMI and physical activity, with no differences between men and women. 605
People with T2D demonstrated greater reductions in MVCC power, MVIC torque and twitch 606 amplitude after the dynamic fatiguing contraction compared with the healthy controls, indicating 607 fatigability and impairments in muscle contractile properties were greater for people with T2D. 608
Voluntary activation was reduced, and the superimposed twitch amplitude and EMG silent 609 period increased after the dynamic fatiguing task, demonstrating reduced neural drive and 610 possibly increased intracortical and spinal inhibition; however, these changes were similar for 611 people with T2D and controls of both sexes. Thus, both muscular and neural mechanisms 612 (including supraspinal fatigue) contributed to knee extensor fatigability of men and women after 613 single limb dynamic exercise, however, contractile mechanisms were responsible for the greater 614 fatigability of people with T2D compared with controls. Accordingly, the primary measures of 615 fatigability, both the reduction in MVCC power and in the MVIC torque, were correlated with 616 the reduction in potentiated twitch amplitude. Estimated maximal oxygen consumption (VO 2 ) at 617 baseline and metabolic factors (HbA 1c , fasting plasma glucose and insulin) were also associated 618 with reduction in MVCC power during the dynamic fatiguing task. 619
A strength of this study was that we designed it to understand the effects of T2D on 620 fatigability of lower limb muscles, while controlling for confounding effects of age, diabetic 621 polyneuropathy, daily physical activity levels, and participant anthropometrics, by excluding any 622 patients with clinical signs of diabetic polyneuropathy and by matching groups based on age, 623 physical activity, estimated aerobic fitness, and BMI. Additionally, people with T2D reportedsimilar daily levels of perceived fatigability, sleep quality and depression as the controls, 625
indicating there was minimal influence of perceptions of fatigue that is often associated with 626 advanced diabetes (15) and that may confound exercise-induced fatigue of the lower limb. These 627 findings however may underestimate the group-related differences in fatigability and the 628 contributing mechanisms may have been different if people with T2D who have diabetic 629 polyneuropathy were included in the study. For example, after a 20-repetition, moderate-velocity 630 (120 deg·s -1 ) isokinetic fatiguing task with the knee extensors (28), there was a progressive, 631
albeit not significant, increase in fatigability in people with T2D and diabetic polyneuropathy (37 632 ± 13% reduction of muscle work) compared with people with T2D and no signs of 633 polyneuropathy (34 ± 13%) and healthy controls (30 ± 8%). Additionally, people with T2D and 634 diabetic polyneuropathy demonstrated reduced motor unit number estimates, mean motor unit 635 firing rates, and impaired neuromuscular propagation in upper and lower limb muscles compared 636 to controls (4), which indicates impairments along the motor pathway from corticospinal centers 637 to the interface of the nerve and muscle. These data provide a rationale for an increased role of 638 central mechanisms contributing to fatigability of limb muscles in people with T2D and 639 polyneuropathy, although this has not been examined. 640
Greater Fatigability in People with T2D 641
The greater fatigability of the knee extensors in people with T2D than controls was 642 evidenced by markedly greater reductions in MVCC power (42.8% vs. 26.4% reduction) and 643 MVIC torque at the end of the dynamic tasks (37.6% vs. 26.4% reduction) (Fig. 2) . During the 644 dynamic fatiguing task, there was a reduction in range of motion and rest time between 645 contractions (increased duty cycle) but this was similar for both groups. However, the average 646 applied torque declined more during the fatiguing task for people with T2D than the controls 647 (17.3% vs. 12.0% reduction), thus, each MVCC required relatively less torque for participantswith T2D compared to controls at the end of the fatiguing task. Despite this, the participants with 649 T2D showed larger losses in power than controls. Thus, our study may have underestimated the 650 magnitude of the difference in loss of power between the groups by up to ~5%. These results are 651 consistent with previous research demonstrating greater fatigability for isometric contractions of 652 people with diabetes mellitus (Type 1 or Type 2) of the handgrip (37), dorsiflexor (3), and knee 653 extensor muscles (6). Importantly, our results clearly indicate that the knee extensor muscles are 654 more fatigable for dynamic contractions in people with T2D, although these results are not 655 consistent with that seen for low repetition (20 -30 repetitions), moderate velocity (120 -180 656 deg·s -1 ) isokinetic contractions for this muscle group (18, 28). The greater fatigability of people 657 with T2D in our study, but not others, could be due to faster contraction velocities or more 658 repetitions in our protocol. Close examination of the muscle power during the fatiguing task (Fig.  659   2A) demonstrates that the differences in fatigability between people with T2D and controls did 660 not become apparent until after ~60 repetitions. Thus, greater fatigability of people with T2D 661 may only occur with more repetitions or faster contraction velocities, and the magnitude of the 662 difference in fatigability between people with T2D and controls likely increases as a function of 663 exercise time. 664
A unique aspect of our study was that our cohort of T2D participants did not have 665 advanced stages of the disease, yet lower limb fatigue was greater than in controls matched for 666 age, BMI and physical activity. Many of the processes associated with advancing severity of 667 T2D will exacerbate fatigability of the lower limb even further, including diabetic 668 polyneuropathy (2) and loss of muscle mass (5), impaired microcirculation (37) and 669 cardiovascular disease. We showed however, that even prior to detectable clinical signs of 670 polyneuropathy and loss of muscle mass, people with T2D display greater fatigability of the knee 671 extensor muscles that are important for daily function, and as discussed below, was due to 672 contractile mechanisms.
